Sanofi is buying U.S. pharmaceutical company Provention Bio for $2.9 billion, or $25 per share. Company is the developer of TZIELD, the only drug approved in the U.S. to slow the onset of Stage 3 Type 1 diabetes. Closing of deal is scheduled for the second quarter of 2023.
Sanofi is buying U.S. pharmaceutical company Provention Bio for $2.9 billion, or $25 per share. Company is the developer of TZIELD, the only drug approved in the U.S. to slow the onset of Stage 3 Type 1 diabetes. Closing of deal is scheduled for the second quarter of 2023. 
sanofi.com
English (US) 